SureTrader SPDR Advertisement
Home > Boards > US Listed > Biotechs >

MannKind Corp. (MNKD)

Add MNKD Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator TREND1, conix, MadHatter326, KingDMC, $Pistol Pete$
Search This Board:
Last Post: 7/28/2015 1:17:35 PM - Followers: 311 - Board type: Free - Posts Today: 6


About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh) is a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. AFREZZA was approved by the FDA in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of AFREZZA. Sanofi is responsible for global commercial, regulatory and development activities and. MannKind manufactures AFREZZA at its manufacturing facility in Danbury, CT.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

- See more at:


Board of Directors

Alfred E. Mann

Alfred E. Mann has been one of our directors since April 1999, our Chairman of the Board since December 2001 and our Executive Chairman since January 2015. He also served as our Chief Executive Officer from October 2003 until January 2015.  Mr. Mann has founded and largely funded 14 companies in his career.  Nine were acquired at an overall total of almost $8 billion, and three companies became public.  In addition to MannKind, he is currently involved with:

• Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs;
• Second Sight, which is developing a visual prosthesis to restore sight to the blind; 
• IncuMed, which is developing novel percutaneous seals for various applications; 
• PerQFlo, which is developing drug delivery systems; and
• RoundTrip, which is developing location and identification technology.

In 1993, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. until August 2001 when it was acquired by Medtronic, Inc.  Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of Type 1 diabetes.  Mr. Mann founded and funded Medical Research Group (MRG), a developer of an artificial pancreas.  MRG was also acquired by Medtronic in 2001.  Mr. Mann also founded and served as the Chairman of the Board and Chief Executive Officer of Advanced Bionics Corporation from its founding in 1993 until it was acquired by Boston Scientific Corporation in 2004.  Advanced Bionics developed neurostimulation devices for various neural deficits, including cochlear stimulators.  Previously, Mr. Mann founded and was Chairman of the Board and CEO of Pacesetter Systems, Inc., which developed, manufactured and distributed cardiac pacemakers, from 1972 until 1985 when it was acquired by Siemens, AG.  From 1985 to September 1992, Mr. Mann continued to serve as Chairman and CEO of the successor company, Siemens-Pacesetter, Inc., Pacesetter is now the Cardiac Rhythm Management unit of St. Jude Medical.  Prior to 1972, he was President of Spectrolab, an electro-optical and aerospace systems company, and Heliotek, a semiconductor and electro-optical components manufacturer.  Mr. Mann founded these companies in 1956 and 1960, respectively, sold them to Textron Inc. in 1960 and continued to lead them until 1972, when he left for Pacesetter.  They are now part of the Boeing Company.
Mr. Mann founded and endowed, and from 1985 until 2006 served as Chairman of the Board of Trustees of The Alfred Mann Foundation, a nonprofit research organization devoted to development of advanced medical products in a variety of fields.  Mr. Mann is currently Chairman of the Board of Trustees of the Alfred Mann Institutes at the University of Southern California, Purdue University, and The Technion Institute (Israel), all of these medical research foundations founded and endowed principally by Mr. Mann.  He also serves as a Trustee for the University of Southern California, as a member of the Board of Overseers of the Keck USC School of Medicine, and as the Chairman of the Southern California Biomedical Council, a nonprofit association dedicated to the fostering of the bio-medical industry in the Los Angeles Metropolitan area.  Alfred Mann also serves as a Director of the Nevada Cancer Institute.
Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel).  Mr. Mann is also a member of the National Academy of Engineering.

Ronald Consiglio


Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge  A good forum for discussion on Mankind

MannKind Corporation, a development stage company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer. Its lead investigational product candidate, the Technosphere Insulin System, is in phase III clinical trials in the United States, Europe, and Latin America for the treatment of diabetes. This dry powder therapy consists of Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using its proprietary MedTone inhaler. The company is also developing therapies for the treatment of solid tumor cancers. The lead product candidate in this program, MKC1106-PP, which is in phase I clinical trial is intended for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, and prostate carcinomas and melanoma. MannKind was founded in 1991 and is headquartered in Valencia, CA.;;


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MNKD News: The Reason MannKind Stock Galloped 10% Higher in June 07/09/2015 08:07:02 AM
MNKD News: 3 Biotech Stocks with Low Liquidity Ratios -- Are They in Trouble? 06/29/2015 09:03:02 AM
MNKD News: What Is a Short Squeeze, and How Can it Affect Your Investments? 06/19/2015 05:08:02 PM
MNKD News: 3 Biotech Stocks That I Won't Buy 06/13/2015 08:04:03 AM
MNKD News: Why MannKind Corp. Stock Bolted Higher Today 06/08/2015 12:06:20 PM
#13500  Sticky Note Afrezza_Sales_Table_+_Analysis JLS 07/27/15 01:40:10 AM
#13483  Sticky Note $MNKD 3 Biotech Stocks with Low Liquidity Ra $Pistol Pete$ 07/25/15 02:35:29 AM
#12078  Sticky Note SHORT INTEREST--As of 5/29/15--131 Million Shares Short conix 06/10/15 10:14:43 AM
#8377  Sticky Note Not Looking Good For MNKD! MadHatter326 02/13/15 02:37:35 PM
#13516   Options trading discussions Jack4656 07/28/15 01:17:35 PM
#13515   MannKind's Afrezza May Reach Larger Diabetic Population Than biginvestors 07/28/15 12:48:29 PM
#13514   Sanofi has been aware of Afrezza for a SidVicious 07/28/15 10:38:23 AM
#13513   Only Mannkind's partner Sanofi not afraid of Afrezza Cave In Temptor 07/28/15 07:24:05 AM
#13512   Why is big Pharma afraid of MannKind? JLS 07/28/15 02:58:44 AM
#13511   Futures are up nicely, Monday_11:23_PDT, JLS 07/28/15 02:23:45 AM
#13510   Why is big Pharma afraid of MannKind. Phaeton 07/27/15 10:59:01 PM
#13509   I agree with your assessment on the market. Hypi 07/27/15 05:30:39 PM
#13508   Not likely a bottom yet, JLS 07/27/15 04:10:57 PM
#13507   MannKind Continues To Decline conix 07/27/15 02:26:13 PM
#13506   When all else fails ... JLS 07/27/15 01:27:00 PM
#13505   Come on Girls bring it on down won't kugel 07/27/15 01:20:19 PM
#13504   Agreed $Pistol Pete$ 07/27/15 11:57:56 AM
#13503   Bring it back to 4.63 and i will kugel 07/27/15 11:16:01 AM
#13502   Interesting.. kugel 07/27/15 10:43:38 AM
#13501   MNKD Sup/Res JLS 07/27/15 02:24:04 AM
#13500   Afrezza_Sales_Table_+_Analysis JLS 07/27/15 01:40:10 AM
#13499   Mnkd under $5??? vip1999 07/26/15 03:45:30 AM
#13497   Your welcome. I was relieved of being a frosr6 07/25/15 05:54:49 PM
#13496   Your welcome frosr6 07/25/15 05:45:10 PM
#13495   No problem frosr6 07/25/15 05:44:48 PM
#13494   When MNKD is in a Big RED.....there is $Pistol Pete$ 07/25/15 04:10:58 PM
#13493   MNKD: Let's get fired up! Denise Chanterelle 07/25/15 12:58:08 PM
#13492   Too funny. Some on another site don't believe SidVicious 07/25/15 11:30:29 AM
#13491   How about corporate subscription? Many staff members COO2002COO 07/25/15 07:39:52 AM
#13490   Short interest down another 2.1 M (18 M Cave In Temptor 07/25/15 06:59:38 AM
#13489   Time Mag great targeted exposure: 16.6 M print Cave In Temptor 07/25/15 06:59:03 AM
#13488   Thanks, Frosr6. I have missed your charts COO2002COO 07/25/15 06:30:48 AM
#13487   I have been following Clayton's charts for quite COO2002COO 07/25/15 06:28:01 AM
#13486   $MNKD is a PUMP & DUMP to make $Pistol Pete$ 07/25/15 02:45:20 AM
#13485   $MNKD The Future Of MannKind Worth $1 $Pistol Pete$ 07/25/15 02:44:03 AM
#13484   $MNKD Analyst Price Target Update on MannKind C $Pistol Pete$ 07/25/15 02:41:59 AM
#13483   $MNKD 3 Biotech Stocks with Low Liquidity Ra $Pistol Pete$ 07/25/15 02:35:29 AM
#13482   Wow! That's cool! Good job SV! Love the Denise Chanterelle 07/25/15 01:02:33 AM
#13481   Thank You missed that chart tyfoidhana 07/25/15 12:59:08 AM
#13480   We use it to for a few stocks, harry crumb 07/25/15 12:56:13 AM
#13479   Sweet! Thx man!!! Looking good! Buying in in Goodfella$ 07/25/15 12:46:26 AM
#13478   Can a mod please remove the outdated sticky thealias2002 07/25/15 12:43:35 AM
#13477   I ripped it out. Here are 2 of SidVicious 07/25/15 12:43:33 AM
#13476   You have any pics?? Or links thanks so much!! Goodfella$ 07/25/15 12:34:56 AM
#13475   Afrezza ad is in the latest Time magazine. SidVicious 07/25/15 12:23:37 AM
#13474   If you are in many bio's, we are TREND1 07/24/15 11:54:38 PM
#13472   I'm with you Mr. Crumb. I'm Long, fully Denise Chanterelle 07/24/15 11:10:02 PM
#13471   We are in many bio's including mnkd, bought harry crumb 07/24/15 10:14:39 PM
#13470   $MNKD it looks really bad and that's why $Pistol Pete$ 07/24/15 07:46:19 PM
#13469   F6 thanks for the info TREND1 07/24/15 07:24:18 PM
#13467   Here ya go frosr6 07/24/15 07:10:20 PM
#13466   no update? Jack4656 07/24/15 06:50:31 PM
#13465   So you are just going to stay in MNKD... TREND1 07/24/15 06:16:16 PM
#13464   I don't recall a question about options. My ClayTrader 07/24/15 05:31:43 PM